溃疡性结肠炎药物治疗的组织学愈合率:随机对照试验的系统评价与Meta分析
该系统评价与Meta分析纳入74项随机对照试验(68项诱导、7项维持),评估氨基水杨酸类、糖皮质激素、免疫抑制剂、生物制剂和小分子药物治疗溃疡性结肠炎的组织学缓解率。局部氨基水杨酸灌肠液和栓剂的组织学缓解率最高,组织学与内镜缓解强相关(r=0.66)。现有治疗的组织学缓解率因药物类别和人群而异,范围为15.0%至44.9%。
要点
- 局部氨基水杨酸灌肠液诱导组织学缓解率37.2%,栓剂44.9%,为各类治疗中最高。
- 氨基水杨酸灌肠液(RR=4.14)、栓剂(RR=3.94)和布地奈德多基质(RR=1.47)的组织学缓解率高于安慰剂。
- 组织学与内镜缓解强相关(r=0.66),组织学缓解是潜在的治疗目标。
核心结论
- 现有溃疡性结肠炎治疗的组织学缓解率因药物类别和患者人群而异,范围为15.0%至44.9%,局部氨基水杨酸类最高;这些数据为未来试验设计提供基准,组织学缓解是临床实践中的潜在治疗目标。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE、EMBASE、CENTRAL和Cochrane IBD登记库中氨基水杨酸类、糖皮质激素、免疫抑制剂、生物制剂和小分子的随机对照试验,共纳入74项研究(68项诱导和7项维持)。
主要发现
- 局部氨基水杨酸灌肠液诱导组织学缓解率为37.2%(95%CI 29.0-46.3),栓剂为44.9%(95%CI 28.9-62.3),为诱导缓解率最高。
- 氨基水杨酸灌肠液(RR=4.14,95%CI 2.35-7.31)、氨基水杨酸栓剂(RR=3.94,95%CI 1.26-12.32)和布地奈德多基质(RR=1.47,95%CI 1.08-1.99)的组织学缓解率高于安慰剂。
- 诱导研究中安慰剂的组织学缓解率为10.4%(95%CI 7.1-15.2);组织学与内镜缓解强相关(r=0.66,95%CI 0.50-0.78)。
- 多变量分析显示,安慰剂组中较不严重的临床疾病活动和皮质类固醇使用与较高的组织学缓解率相关;活动治疗组中轻度临床疾病活动与较高的组织学缓解率相关。
临床怎么用
- 作者认为组织学缓解是临床实践中的潜在治疗目标。
局限性
- 生物制剂和免疫抑制剂的组织学缓解数据缺乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Histologic remission is a potentially valuable means of assessing disease activity and treatment response in ulcerative colitis (UC). However, the efficacy of existing therapies to achieve this outcome is unclear. We performed a systematic review and meta-analysis of histologic outcomes in UC randomized controlled trials and examined the relationship between histologic and endoscopic outcomes. METHODS: MEDLINE, EMBASE, CENTRAL, and the Cochrane IBD Register were searched for randomized controlled trials of aminosalicylates, corticosteroids, immunosuppressives, biologics, and small molecules. Histologic and endoscopic remission and response data were independently extracted and pooled using binomial-normal random-effect or fixed-effect models. Pooled efficacy estimates were calculated as risk ratios (RRs) using the Mantel-Haenszel method. Univariable and multivariable random-effect meta-regression models examined factors associated with histologic remission. RESULTS: Seventy-four studies (68 induction and 7 maintenance) were identified. Topical aminosalicylate enemas [37.2%, 95% confidence interval (CI), 29.0-46.3] and suppositories (44.9%, 95% CI, 28.9-62.3) had the highest induction of histologic remission rates. Aminosalicylate enemas (RR = 4.14, 95% CI, 2.35-7.31), aminosalicylate suppositories (RR = 3.94, 95% CI, 1.26-12.32), and budesonide multimatrix (RR = 1.47, 95% CI 1.08-1.99) had higher histologic remission rates than placebo. Data were lacking for biologics and immunosuppressives. The pooled histologic remission rate for placebo in induction studies was 10.4% (95% CI, 7.1-15.2). Histologic and endoscopic remission correlated strongly (r = 0.66; 95% CI, 0.50-0.78). In multivariate analysis of placebo-arm data, less severe clinical disease activity and corticosteroid use were associated with higher histologic remission rates. Similarly, mild clinical disease activity was associated with higher histologic remission rates when active-arm data were analyzed. CONCLUSIONS: Histologic remission rates for current UC treatments ranged from 15.0% to 44.9% according to drug class and patient population with the highest rates observed for topical aminosalicylates. Placebo remission rates were low with relatively narrow CIs. These data provide benchmarks to inform future trial design. Histologic remission is a potential treatment target in clinical practice.
引用
- Battat R, Duijvestein M, Guizzetti L, et al. Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Gastroenterol. 2019. PMID: 30694863. doi:10.14309/ajg.0000000000000111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。